Paracoccidioidomycosis: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
Line 35: Line 35:
==Related Chapters==
==Related Chapters==
* [[Paracoccidioides brasiliensis]]
* [[Paracoccidioides brasiliensis]]
== Treatment==
[[Sulphonamide]]s are the traditional remedies to paracoccidiodomycosis. They were introduced by Oliveira Ribeiro and used for more than fifty years with good results. The most used [[sulfa drugs]] in this infection are sulfadimethoxime, [[sulfadiazine]] and [[co-trimoxazole]]. This treatment is generally safe but several adverse effects can appear, the most severe of which are the [[Stevens Johnson Syndrome]] and [[agranulocytosis]]. It must be continued for up to 3 years to obtain cure and relapse and treatment failures aren't unusual.
Antifungal drugs like [[Amphotericin B]] or [[Ketoconazole]] are also effective in clearing the infection but they are very expensive compared with sulphonamides.
During therapy [[fibrosis]] can appear and a surgery be needed to correct this. Other possible complication is Addisonian crisis. The death rate is around ten percent.
===Antimicrobial Regimen===
*'''Paracoccidioidomycosis''' <ref name="pmid16906260">{{cite journal| author=Shikanai-Yasuda MA, Telles Filho Fde Q, Mendes RP, Colombo AL, Moretti ML| title=[Guidelines in paracoccidioidomycosis]. | journal=Rev Soc Bras Med Trop | year= 2006 | volume= 39 | issue= 3 | pages= 297-310 | pmid=16906260 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16906260  }} </ref>
:* Preferred regimen (1):
::* Adults: [[Itraconazole]] 200 mg/day PO
::* Children: [[Itraconazole]] (<30/kg and >5 yr) 5-10 mg/kg/day PO
::*Note: Treatment duration based on organ involvement:
:::*Mild involvement: 6-9 months
:::*Moderate involvement: 12-18 months
:* Preferred regimen (2)
::* Adults: [[Trimethoprim/sulfamethoxazole]] (TMP/SMX)  TMP: 160-240 mg/day PO/IV, SMX: 800-1200 mg/day PO/IV bid
::* Children: [[Trimethoprim/sulfamethoxazole]] (TMP/SMX) TMP: 8-10 mg/kg PO/IV, SMX: 40-50 mg/kg PO/IV, bid
::* Note (1): Treatment duration based on organ involvement:
:::* Minor involvement: 12 months
:::* Moderate involvement: 18-24 months
::*Note (2): Preferred treatment in children due to larger experience.
::*Note (3): Preferred in IV formulation in severe forms of the disease - 2 ampules IV tid until patient condition improves so that oral medication can be given.
:* Preferred regimen (3): [[Amphotericin B]] deoxycholate 1 mg/kg/day IV until patient improves and can be treated by the oral route.
::*Note: Preferred in severe forms of the disease.
:* Alternative regimen (4): [[Ketoconazole]] 200-400 mg/day PO for 9-12 months<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref>
:* Alternative regimen (5): [[Voriconazole]] initial dose 400 mg PO/IV q12h for one day, then 200 mg q12h for 6 months<ref>{{cite book | last = Bennett | first = John | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Elsevier/Saunders | location = Philadelphia, PA | year = 2015 | isbn = 978-1455748013 }}</ref>
::* Note: Diminish the dose to 50% if weight is <40 kg.
==External links==
* {{MerckManual|13|158|e}}
* [http://www.mycology.adelaide.edu.au/Mycoses/Dimorphic_systemic/Paracoccidioidomycosis/ Overview] at University of Adelaide
{{Mycoses}}
[[es:Paracoccidioidomicosis]]
[[it:Paracoccidioidomicosi]]
[[pt:Paracoccidioidomicose]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Revision as of 15:14, 5 August 2015

Paracoccidioidomycosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Paracoccidioidomycosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Paracoccidioidomycosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Paracoccidioidomycosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Paracoccidioidomycosis

CDC on Paracoccidioidomycosis

Paracoccidioidomycosis in the news

Blogs on Paracoccidioidomycosis

Directions to Hospitals Treating Paracoccidioidomycosis

Risk calculators and risk factors for Paracoccidioidomycosis

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Paracoccidioidomycosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | CT | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case#1

Related Chapters